Almitas Capital LLC Makes New Investment in Alto Neuroscience, Inc. (NYSE:ANRO)

Almitas Capital LLC purchased a new position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 266,912 shares of the company's stock, valued at approximately $1,129,000. Almitas Capital LLC owned approximately 0.99% of Alto Neuroscience at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock worth $13,965,000 after acquiring an additional 595,673 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Alto Neuroscience by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company's stock valued at $3,575,000 after purchasing an additional 36,319 shares in the last quarter. Marshall Wace LLP purchased a new stake in Alto Neuroscience in the 4th quarter worth about $3,542,000. Northern Trust Corp boosted its position in Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company's stock worth $2,484,000 after acquiring an additional 390,190 shares during the period. Finally, Geode Capital Management LLC grew its stake in Alto Neuroscience by 148.7% during the 3rd quarter. Geode Capital Management LLC now owns 469,988 shares of the company's stock valued at $5,378,000 after acquiring an additional 281,018 shares in the last quarter.

Alto Neuroscience Stock Performance

Alto Neuroscience stock traded down $0.02 during trading hours on Friday, hitting $2.43. The stock had a trading volume of 157,599 shares, compared to its average volume of 380,411. The company has a market cap of $65.81 million, a PE ratio of -0.96 and a beta of 1.87. Alto Neuroscience, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $17.55. The company has a 50-day moving average of $2.56 and a two-hundred day moving average of $3.77. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09. On average, equities research analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANRO has been the subject of a number of research analyst reports. HC Wainwright started coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They issued a "buy" rating and a $10.00 target price for the company. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.40.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.